InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

TScan Therapeutics, Inc.

TCRX Clue Score37
United States Fiscal year ends December CIK 0001783328
$0.24 +4.29% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.24 −96.70% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 16 Jul 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2020Revenue1.1Operating income−26.2Net income−26.1Fiscal year 2021Revenue10.1 +834.7%Operating income−48.6Net income−48.6EPS, diluted−4.17Fiscal year 2022Revenue13.5 +33.5%Operating income−66.6Net income−66.2EPS, diluted−2.75Fiscal year 2023Revenue21.0 +55.5%Operating income−93.5Net income−89.2EPS, diluted−1.36Fiscal year 2024Revenue2.8 −86.6%Operating income−134.8Net income−127.5EPS, diluted−1.14Fiscal year 2025Revenue10.3 +266.7%Operating income−135.8Net income−129.8EPS, diluted−1.00
FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 1.1 10.1 13.5 21.0 2.8 10.3
Growth +834.7% +33.5% +55.5% −86.6% +266.7%
Operating income −26.2 −48.6 −66.6 −93.5 −134.8 −135.8
Net income −26.1 −48.6 −66.2 −89.2 −127.5 −129.8
Growth
EPS, diluted n/a −4.17 −2.75 −1.36 −1.14 −1.00

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2020Operating margin−2,417.8%Net margin−2,408.0%Free cash flow margin−669.2%Fiscal year 2021Operating margin−479.6%Net margin−479.5%Free cash flow margin−578.0%Fiscal year 2022Operating margin−492.3%Net margin−489.3%Free cash flow margin−522.6%Fiscal year 2023Operating margin−444.0%Net margin−423.9%Free cash flow margin−306.4%Fiscal year 2024Operating margin−4,787.7%Net margin−4,527.7%Free cash flow margin−4,071.3%Fiscal year 2025Operating margin−1,315.4%Net margin−1,256.8%Free cash flow margin−1,353.3%
FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin −2,417.8% −479.6% −492.3% −444.0% −4,787.7% −1,315.4%
Net margin −2,408.0% −479.5% −489.3% −423.9% −4,527.7% −1,256.8%
Free cash flow margin −669.2% −578.0% −522.6% −306.4% −4,071.3% −1,353.3%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2020Operating cash flow−3.0Capital expenditure−4.2Free cash flow−7.3Fiscal year 2021Operating cash flow−48.7Capital expenditure−9.9Free cash flow−58.6Fiscal year 2022Operating cash flow−66.5Capital expenditure−4.2Free cash flow−70.7Fiscal year 2023Operating cash flow−61.4Capital expenditure−3.1Free cash flow−64.5Fiscal year 2024Operating cash flow−110.8Capital expenditure−3.8Free cash flow−114.6Fiscal year 2025Operating cash flow−135.3Capital expenditure−4.4Free cash flow−139.7
FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −3.0 −48.7 −66.5 −61.4 −110.8 −135.3
Capital expenditure −4.2 −9.9 −4.2 −3.1 −3.8 −4.4
Free cash flow −7.3 −58.6 −70.7 −64.5 −114.6 −139.7
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2020Cash34.8Shareholders’ equity−42.5Fiscal year 2021Cash161.4Shareholders’ equity160.8Fiscal year 2022Cash120.0Total debt29.3Net cash (debt)90.7Shareholders’ equity99.4Debt to equity0.29Fiscal year 2023Cash133.4Total debt30.0Net cash (debt)103.3Shareholders’ equity150.9Debt to equity0.20Fiscal year 2024Cash178.7Total debt32.1Net cash (debt)146.6Shareholders’ equity241.0Debt to equity0.13Fiscal year 2025Cash152.4Total debt32.5Net cash (debt)119.9Shareholders’ equity123.1Debt to equity0.26
FY2020FY2021FY2022FY2023FY2024FY2025
Cash 34.8 161.4 120.0 133.4 178.7 152.4
Total debt n/a n/a 29.3 30.0 32.1 32.5
Net cash (debt) n/a n/a 90.7 103.3 146.6 119.9
Shareholders’ equity −42.5 160.8 99.4 150.9 241.0 123.1
Debt to equity n/a n/a 0.29 0.20 0.13 0.26

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022† 31 Dec 2022 FY2023† 31 Dec 2023 FY2024† 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
1.1 10.1 13.5 21.0 2.8 10.3
Growth +834.7% +33.5% +55.5% −86.6% +266.7%
20.6 45.0 59.8 88.2 107.4 114.2
6.7 13.8 20.4 26.4 30.3 32.0
−26.2 −48.6 −66.6 −93.5 −134.8 −135.8
Growth
n/a n/a n/a n/a n/a 0.0
−26.1 −48.6 −66.2 −89.2 −127.5 −129.8
Growth
Per share
n/a −4.17 −2.75 −1.36 −1.14 −1.00
n/a −4.17 −2.75 −1.36 −1.14 −1.00
Growth
n/a 11.7 24.0 65.6 112.0 129.8
n/a 11.7 24.0 65.6 112.0 129.8
Growth +106.2% +172.8% +70.7% +15.9%

† The diluted share count jumps at 2022 and 2023 and 2024, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • Revenue grew 56.9% a year over five years.
  • Operating margin is up 1,102.4 points on five years ago, at -1,315.4%.
  • A net loss in 6 of 6 years on file.